Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/13/2019 03/14/2019 03/15/2019 03/18/2019 03/19/2019 Date
46.6(c) 47.9(c) 48.56(c) 47.84(c) 48.04 Last
60 998 44 680 50 358 40 390 4 429 Volume
+0.30% +2.79% +1.38% -1.48% +0.42% Change
More quotes
Financials (CHF)
Sales 2019 132 M
EBIT 2019 -26,5 M
Net income 2019 -31,8 M
Debt 2019 53,3 M
Yield 2019 -
Sales 2020 158 M
EBIT 2020 8,80 M
Net income 2020 3,47 M
Debt 2020 78,8 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 4,70x
EV / Sales2020 4,10x
Capitalization 568 M
More Financials
Company
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of... 
Sector
Biotechnology & Medical Research
Calendar
04/10 | 09:00amShareholder meeting
More about the company
Surperformance© ratings of Basilea Pharmaceutica AG
Trading Rating : Investor Rating :
More Ratings
Latest news on BASILEA PHARMACEUTICA AG
02/19BASILEA PHARMACEUTICA : reports strong revenue growth and significant pipeline p..
AQ
02/08Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milesto..
GL
02/07Basilea announces change in the Management Committee - Adesh Kaul appointed C..
GL
02/07BASILEA PHARMACEUTICA : announces change in the Management Committee - Adesh Kau..
GL
01/25Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecen..
AQ
01/24Basilea announces collaboration to study derazantinib and atezolizumab (Tecen..
GL
01/24BASILEA PHARMACEUTICA : announces collaboration to study derazantinib and atezol..
GL
01/09BASILEA PHARMACEUTICA : reports positive interim results from registrational pha..
AQ
01/07BASILEA PHARMACEUTICA : reports strong, higher than expected preliminary revenue..
GL
01/07Basilea reports strong, higher than expected preliminary revenue of CHF 133 m..
GL
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Sector news : Biotechnology & Medical Research - NEC
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 88,3  CHF
Spread / Average Target 85%
EPS Revisions
Managers
NameTitle
David Veitch Chief Executive Officer
Domenico Scala Chairman
Donato Spota Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BASILEA PHARMACEUTICA AG19.72%568
IQVIA HOLDINGS INC21.83%27 995
CELLTRION, INC.--.--%22 910
LONZA GROUP17.79%22 285
INCYTE CORPORATION33.35%18 151
SEATTLE GENETICS, INC.31.70%11 981